Vaxart (VXRT) Reports Q1 Loss of $0.14/sh

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/21/2026

1. SPCX
2. NVDA
3. NFLX
4. ISRG
5. TSLA
6. META
7. RTX
8. SMCI
9. GOOGL
10. S

Go back to Vaxart (VXRT) Reports Q1 Loss of $0.14/sh

Vaxart Reports First Quarter 2021 Financial Results and Provides Business Update

May 3, 2021 8:00 AM EDT

Vaxart to advance three oral tablet COVID-19 vaccine candidates to the clinic: VXA-CoV2-1 (includes both the S and the N proteins) into Phase II and two S-only constructs into Phase I/IIFour clinical trials of the oral norovirus vaccine candidate to be initiated in 2021Cash, cash equivalents, and marketable securities of $177.3 million as of March 31, 2021

SOUTH SAN FRANCISCO, Calif., May 03, 2021 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT), a clinical-stage biotechnology... More